4 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 enrolling by invitation. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Not yet recruiting 3, Active not recruiting 1, Enrolling by invitation 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow TNBC: new trials by email Literature Review of TNBC trials Research Report on TNBC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Live biotherapeutic product: MO-03 1 capsule PO BID - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Yuan Yuan | 50 | 2026-09-01 | 2026-08-05 |
| A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation Inavolisib in Combination With Eribulin - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Hu Hai | 26 | 2026-03-15 | 2026-03-02 |
| Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases Sacituzumab Tirumotecan (Sac-TMT), bevacizumab - TNBC, Brain Metastasis | Phase 2 | Recruiting | Fudan University | 24 | 2026-01-01 | 2026-06-03 |
| A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxel - TNBC | Phase 2 | Enrolling by invitation | Huabo Biopharm Co., Ltd. | 60 | 2025-08-14 | 2026-01-29 |
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Ivonescimab, Carboplatin, Docetaxel - TNBC, TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 34 | 2025-07-25 | 2026-08-04 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer IMM2510, Chemotherapy (pemetrexed + cisplatin/carboplatin), Chemotherapy (paclitaxel + cisplatin/carboplatin) - NSCLC, TNBC | Phase 2 | Not yet recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 148 | 2024-12-01 | 2024-12-24 |
| SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases SHR-A1921 + Bevacizumab - TNBC, Brain Metastasis | Phase 2 | Unknown | Fudan University | 24 | 2024-02-01 | 2024-01-18 |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC PM8002, nab-paclitaxel - TNBC | Phase 1 / Phase 2 | Active not recruiting | Biotheus Inc. | 42 | 2022-07-01 | 2025-03-11 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Triple Negative Breast Neoplasms (5) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms by Site (7) · Neoplasms (6) · Breast Diseases (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Neoplasms (4) · Brain Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Female Urogenital Diseases (2)
130-nm albumin-bound paclitaxel (2) · Bevacizumab (2) · Carboplatin (2) · Cisplatin (1) · Docetaxel (1) · Drug Therapy (1) · Paclitaxel (1) · Pemetrexed (1) · eribulin (1) · inavolisib (1) · pembrolizumab (1)
Fudan University (2) · A2 Biotherapeutics Inc. (1) · Biotheus Inc. (1) · Cedars-Sinai Medical Center (1) · Hu Hai (1) · Huabo Biopharm Co., Ltd. (1) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) · PMV Pharmaceuticals, Inc (1) · Yuan Yuan (1)
China (4) · United States (4) · Australia (1) · France (1) · Germany (1) · Italy (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Yuan Yuan, MD (2) · Jin Sun Lee-Bitar, MD (1) · John Welch, MD, PhD (1) · Marc Fellous, MD (1) · Qiying Lu, MD (1) · Wu Jiong (1)